Improving Outcomes in Lipid Management: Aligning Managed Care Policy With Emerging Guideline Updates and Non-Statin Therapeutic Advances

Program Description

Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of morbidity and mortality worldwide, and complications arising from ASCVD have been associated with greater health care resource utilization as well as increased direct and indirect costs. Effective lipid management, centered on the reduction of LDL-C, is the cornerstone of secondary prevention; however, a substantial proportion of high-risk patients fall short of meeting guideline-recommended targets on statin monotherapy. This program is designed to equip managed care professionals and pharmacists with strategies to advance value-based hyperlipidemia care by utilizing evidence-based risk stratification tools and ensuring guideline adherence. The latest clinical trial data and expanded FDA indications for non-statin therapies as well as emerging LDL-C-lowering therapies will be discussed. Beyond pharmacotherapy, the session will address the logistical side of lipid management, focusing on navigating prior authorization and benefit design to ensure timely identification and treatment initiation among patients that may benefit from non-statin therapies.

Target audience: Managed care pharmacists
Type of activity: Application
Release date: June 30, 2026
Expiration date: June 30, 2027
Learner level: Foundational, Intermediate
Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Factor data on the clinical burden of atherosclerotic cardiovascular disease into evidence-based risk-stratification and lipid-biomarker evaluation for patients who require early cardiovascular intervention
• Interpret updated clinical guideline recommendations discussing the progression, efficacy, and safety of established and emerging non-statin lipid-lowering therapies
• Identify population-health approaches to support high-risk patients, enhancing access to non-statin therapies and advancing value-based care through timely treatment

Accreditation

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.10CEU) under the ACPE universal activity number 0290-9999-26-201-H01-P The activity is available for CE credit through June 30, 2027

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Faculty

Steven Kheloussi, PharmD, MBA, FAMCP, has nothing to disclose

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Liza Patel, PharmD; Macara Desai; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with ineligible companies to disclose.

Any relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

Continuing professional education activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved by the labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com

Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms